Drug Type AAV based gene therapy |
Synonyms AVA-201 - Avalon GloboCare, MSC-EV-miR-185, MSC-Exo-miR185 + [3] |
Target- |
Mechanism RNA interference |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Wet age-related macular degeneration | Phase 2 | AU | 19 Dec 2011 | |
Leukoplakia | Preclinical | US | - | |
Mouth Neoplasms | Preclinical | US | - |
Phase 2 | 32 | ranibizumab+rAAV.sFLT-1 | tkrlvwgrto(zdrjoxhumn) = none of the serious AEs were associated with rAAV.sFLT-1. lmxnbedykr (xkzxoujuxo ) | Positive | 01 Dec 2016 | ||
ranibizumab | |||||||
Phase 2 | Wet age-related macular degeneration AAV2 neutralizing antibodies (nAb) | - | nzgckpxspe(sazbzrjqln) = Transient AE pbjrqkajgb (gctoceaeis ) View more | - | 01 May 2016 | ||
rAAV.sFlt-1 |